Stockscreener 앱 받기
48.87
4.56%
2.13
시간 외 거래:
48.87
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Cytokinetics (CYTK) Stock Rises on New Licensing Deal - GuruFocus.com
Why Cytokinetics Stock Was a Nearly 5% Winner Today - MSN
Spinal Muscular Atrophy Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and MOA, ROA by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme Corp - The Globe and Mail
Cytokinetics stock rises on Sanofi's rights acquisition By Investing.com - Investing.com Canada
HC Wainwright Reiterates "Buy" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat
Sanofi: acquisition of aficamten rights for China - Marketscreener.com
Cytokinetics, Incorporated Announces Sanofi Acquires Exclusive Rights to Develop and Commercialize Aficamten from Corxel Pharmaceuticals - Marketscreener.com
Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China - The Manila Times
Calculating The Fair Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) - Yahoo Finance
Franklin Resources Inc. Sells 1,820,114 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics (NASDAQ:CYTK) Given New $82.00 Price Target at Royal Bank of Canada - MarketBeat
Cytokinetics CFO to assume additional role after officer departs By Investing.com - Investing.com Australia
Geode Capital Management LLC Raises Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Wendall Wierenga Sells 742 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) Stock - MarketBeat
Cytokinetics director Wendall Wierenga sells $36,068 in stock By Investing.com - Investing.com Canada
Cytokinetics CFO to assume additional role after officer departs - Investing.com
Cytokinetics' SWOT analysis: aficamten's potential reshapes cardiac drug stock - Investing.com
Cytokinetics' SWOT analysis: aficamten's potential reshapes cardiac drug stock By Investing.com - Investing.com UK
A Look At The Intrinsic Value Of Cytokinetics, Incorporated (NASDAQ:CYTK) - Simply Wall St
Cytokinetics director John Henderson sells $89,747 in stock By Investing.com - Investing.com Australia
Cytokinetics director John Henderson sells $89,747 in stock - Investing.com India
Insider Sell: Fady Malik Sells 7,300 Shares of Cytokinetics Inc (CYTK) - GuruFocus.com
Cytokinetics EVP sells shares worth $369,639 By Investing.com - Investing.com Nigeria
Cytokinetics EVP sells shares worth $369,639 - Investing.com India
Two Sigma Advisers LP Makes New $11.34 Million Investment in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics, Incorporated (NASDAQ:CYTK) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
BNP Paribas Financial Markets Reduces Stake in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Why Is Cytokinetics (CYTK) Down 9.7% Since Last Earnings Report? - Yahoo Finance
Cytokinetics, Incorporated (NASDAQ:CYTK) Stock Holdings Lifted by Janus Henderson Group PLC - MarketBeat
FDA Sets Goal Date for Lymphoma Drug Columvi - Managed Healthcare Executive
Redmile Group LLC Sells 14,751 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Initiates Confirmatory Study on Heart Failure Drug - MSN
Cytokinetics, Incorporated (NASDAQ:CYTK) Shares Sold by Melqart Asset Management UK Ltd - MarketBeat
HighVista Strategies LLC Invests $531,000 in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Cytokinetics Grants New Hires $1.8M+ Stock Options and RSU Package as Employment Incentive | CYTK Stock News - StockTitan
FDA Sets Goal Date for Cardiomyopathy Drug, Aficamten - Managed Healthcare Executive
FDA Accepts Cytokinetics' Application for Cardiovascular Drug - Yahoo Finance
Daily Digest: Sale of former Raiders HQ falls through; Oakland's credit rating cut - The Business Journals
Stock Watch: AHA Conference Disappointments - Scrip
Cytokinetics Launches Major Phase 3 Heart Failure Trial with 1,800 Patient Target | CYTK Stock News - StockTitan
FDA kicks off review of Cytokinetics' aficamten for HCM - pharmaphorum
Erste Asset Management GmbH Invests $3.16 Million in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
FDA accepts Cytokinetics' New Drug Application for HCM By Investing.com - Investing.com Canada
The Manufacturers Life Insurance Company Boosts Position in Cytokinetics, Incorporated (NASDAQ:CYTK) - MarketBeat
Cytokinetics to Present at Evercore ISI and Piper Sandler Healthcare Conferences - StockTitan
Cytokinetics Announces FDA Acceptance of New Drug Application for Aficamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy - The Manila Times
Cytokinetics' HCM Drug Aficamten Advances with FDA Filing Acceptance, 2025 Review Date - StockTitan
Novocure device succeeds in pancreatic cancer study; FDA sets Cytokinetics decision date - Yahoo Finance
2.88%
2.65%
자본화:
|
볼륨(24시간):